TP53 and B-cell chronic lymphocytic leukemia: VenR demonstrates meaningful PFS for all high-risk subgroups, however, PFS following VenR was shorter for RR CLL with umIGHV, TP53 aberrancy, and genomic complexity (≥3 copy number alterations) [14].